<unk>  is a kinase inhibitor that is FDA approved for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.   Common adverse reactions include fatigue, constipation, edema and myalgia (≥20%).
Alectinib
Toceranib
Brigatinib
Regorafenib
Gilteritinib
Encorafenib
Lorlatinib
Fostamatinib